Aldeyra Therapeutics, Inc., a biotechnology company, focuses on the development of products for inflammation, inborn errors of metabolism, and other diseases in the United States and internationally. It is developing ADX-102, a small molecule designed to trap and allow for the degradation of aldehydes, as well as ADX-103 and ADX-104 novel candidates for the treatment of noninfectious anterior uveitis, allergic conjunctivitis, dry eye syndrome, sjögren-larsson syndrome, and succinic semi-aldehyde dehydrogenase deficiency. Aldeyra Therapeutics, Inc. has a collaborative research agreement with Janssen Research & Development, LLC for the development of novel immune-modulating drugs for systemic inflammatory diseases. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was founded in 2004 and is headquartered in Lexington, Massachusetts.

Outperform Votes

Underperform Votes

Community Sentiment

Aldeyra Therapeutics has received 55.03% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Aldeyra Therapeutics and other stocks. Vote “Outperform” if you believe ALDX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ALDX will underperform the S&P 500 over the long term. You may vote once every thirty days.

4.0 Company Ownership

In the past three months, Aldeyra Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $110,000.00 in company stock and sold $0.00 in company stock.

Miscellaneous

Receive ALDX News and Ratings via Email

Sign-up to receive the latest news and ratings for ALDX and its competitors with MarketBeat's FREE daily newsletter.

Aldeyra Therapeutics (NASDAQ:ALDX) Frequently Asked Questions

How has Aldeyra Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Aldeyra Therapeutics' stock was trading at $2.79 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, ALDX shares have increased by 73.1% and is now trading at $4.83. View which stocks have been most impacted by Coronavirus.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aldeyra Therapeutics in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Aldeyra Therapeutics.

What price target have analysts set for ALDX?

4 equities research analysts have issued 12 month target prices for Aldeyra Therapeutics' stock. Their forecasts range from $15.00 to $33.00. On average, they expect Aldeyra Therapeutics' stock price to reach $26.50 in the next year. This suggests a possible upside of 448.7% from the stock's current price. View analysts' price targets for Aldeyra Therapeutics.

Has Aldeyra Therapeutics been receiving favorable news coverage?

Media coverage about ALDX stock has trended extremely negative this week, InfoTrie Sentiment Analysis reports. The research group identifies negative and positive media coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Aldeyra Therapeutics earned a news impact score of -5.0 on InfoTrie's scale. They also gave media coverage about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the stock's share price in the next several days. View the latest news aboutAldeyra Therapeutics.

Are investors shorting Aldeyra Therapeutics?

Aldeyra Therapeutics saw a increase in short interest during the month of May. As of May 15th, there was short interest totaling 483,600 shares, an increase of 18.3% from the April 30th total of 408,900 shares. Based on an average daily trading volume, of 282,700 shares, the short-interest ratio is currently 1.7 days. Currently, 1.8% of the shares of the stock are sold short. View Aldeyra Therapeutics' Current Options Chain.

Which major investors are selling Aldeyra Therapeutics stock?

ALDX stock was sold by a variety of institutional investors in the last quarter, including Nuveen Asset Management LLC, Weiss Multi Strategy Advisers LLC, UBS Group AG, Hikari Power Ltd, Deutsche Bank AG, State Street Corp, Parametric Portfolio Associates LLC, and Bank of New York Mellon Corp. View insider buying and selling activity for Aldeyra Therapeutics.

How do I buy shares of Aldeyra Therapeutics?

Shares of ALDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Aldeyra Therapeutics' stock price today?

One share of ALDX stock can currently be purchased for approximately $4.83.

How big of a company is Aldeyra Therapeutics?

Aldeyra Therapeutics has a market capitalization of $143.89 million. The biotechnology company earns $-60,830,000.00 in net income (profit) each year or ($2.05) on an earnings per share basis.